Search Thermo Fisher Scientific
Search Thermo Fisher Scientific
General Description
Applications
• It blocks product ion of mevalonate, a critical compound in the production of cholesterol and isoprenoids
• It can increase cellular resistance to anticancer agents such as doxorubicin • It can induce apoptosis in myeloma cells
• It can cause cell cycle arrest in G1 and G2/M phase
• It also blocks PDGF receptor tyrosine phosphorylation and MAP kinase activation by PDGF
Literature References
Tobert, A.J. Efficacy and long-term adverse effect pattern of lovastatin. The American Journal of Cardiology. 1988, 62, (15),J28-J34.
Jones, P. MD; Kafonek, S. MD; Laurora, I. PharmD; Donald Hunninghake MD. Comparative Dose Efficacy Study of Atorvastatin VersusSimvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study). The American Journal of Cardiology. 1998, 81, (5),582-587.